Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XB6K | ISIN: US4277461020 | Ticker-Symbol: AXD2
Tradegate
21.11.24
08:01 Uhr
1,046 Euro
-0,022
-2,06 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
HERON THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
HERON THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0491,08012:37
1,0491,08012:28

Aktuelle News zur HERON THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
HERON THERAPEUTICS Aktie jetzt für 0€ handeln
12.11.Heron Therapeutics, Inc.: Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance131Reported positive YTD 2024 Adjusted EBITDA of $1.4 million Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million ZYNRELEF® (bupivacaine...
► Artikel lesen
12.11.HERON THERAPEUTICS, INC. /DE/ - 8-K, Current Report2
04.11.HERON THERAPEUTICS, INC. /DE/ - 8-K, Current Report12
25.09.Heron Therapeutics' (HRTX) Buy Rating Reiterated at Needham & Company LLC34
25.09.Heron Therapeutics' Zynrelef Vial Access Needle Receives FDA Approval3
25.09.Heron Therapeutics, Inc.: Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ("VAN")136- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time - The VAN is expected to launch in Q4 2024 SAN DIEGO, Sept. 25, 2024 /PRNewswire/...
► Artikel lesen
03.09.Heron Therapeutics Taps Brett Fleshman as Chief Business Officer6
09.08.Earnings call: Heron Therapeutics experienced a 15% increase in revenues4
06.08.Heron Therapeutics GAAP EPS of -$0.06 misses by $0.02, revenue of $36.02M beats by $0.13M11
06.08.HERON THERAPEUTICS, INC. /DE/ - S-8, Securities to be offered to employees in employee benefit plans3
06.08.Heron Therapeutics, Inc.: Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance113Second quarter Net Product Sales of $36.0 million, which increased from $31.8 million for the same period in 2023 ZYNRELEF® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024 ZYNRELEF...
► Artikel lesen
15.07.Heron Therapeutics, Inc.: Heron Therapeutics Announces the Inclusion of ZYNRELEF as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System112SAN DIEGO, July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that ZYNRELEF® (bupivacaine...
► Artikel lesen
02.07.Heron Therapeutics announces acceptance of PAS application for dual-acting anesthetic17
02.07.HERON THERAPEUTICS, INC. /DE/ - 8-K, Current Report7
02.07.Heron Therapeutics, Inc.: Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ("VAN")161-The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 SAN DIEGO, July 2, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
► Artikel lesen
18.06.HERON THERAPEUTICS, INC. /DE/ - 8-K, Current Report8
29.05.Heron Therapeutics Submits Prior Approval Supplement To FDA For Zynrelef VAN9
29.05.Heron Therapeutics, Inc.: Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF Vial Access Needle ("VAN")271SAN DIEGO, May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior Approval Supplement...
► Artikel lesen
29.05.HERON THERAPEUTICS, INC. /DE/ - 8-K, Current Report9
07.05.Heron Therapeutics, Inc.: Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates246Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from $(0.27) for the same period in 2023. Launched partnership...
► Artikel lesen
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1